Home > Dermatology > Personal neoantigen vaccine prompts lasting response in melanoma patients

Personal neoantigen vaccine prompts lasting response in melanoma patients

Journal
Nature Medicine online
Reuters Health - 05/02/2021 - A small number of high-risk melanoma patients have continued to show durable CD4+ and CD8+ T cell responses against the majority of immunizing epitopes originally prompted by receipt of NeoVax, a vaccine targeting multiple personal neoantigens, according to an international group of researchers. "We found vaccine-specific T cells that persist in the peripheral blood of melanoma patients for years and are able to traffic to metastatic tumors," Dr. Patrick A. Ott of Dana-Farber Cancer Institute, in Boston, told Reuters Health by email. "This observation supports the ability of personal neoantigen vaccines to induce durable cancer specific immunity, a critical prerequisite for long-term tumor control." In a paper in Nature Medicine, Dr. Ott and colleagues note that they previously demonstrated that this personal neoantigen long-peptide vaccine was feasible, safe and immunogenic in patients with high-risk melanoma. A separate study s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on